Pliant Therapeutics - PLRX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $45.67
Forecasted Upside: 244.91%
Number of Analysts: 10
Breakdown:
0 Sell Ratings
0 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$13.24 As of 05/8/2024 01:19 PM ET

▼ -0.55 (-3.99%)

1 month | 3 months | 12 months

Get New Pliant Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLRX

^$45.67

▲ +244.91% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $45.67, with a high forecast of $63.00 and a low forecast of $36.00. The average price target represents a 244.91% upside from the last price of $13.24.

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Pliant Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/15/2022

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/13/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/14/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/12/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/10/2023

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/8/2024

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/8/2024

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/8/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/7/2024	Citigroup	Lower Target	Buy ➝ Buy	$45.00 ➝ $44.00	Low
5/7/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$54.00 ➝ $45.00	Low
5/7/2024	Oppenheimer	Boost Target	Outperform ➝ Outperform	$47.00 ➝ $48.00	Low
5/7/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$36.00	Low
5/7/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$38.00	Low
4/10/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$38.00	Low
3/5/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$50.00 ➝ $54.00	Low
2/28/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$48.00	Low
2/28/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$53.00 ➝ $50.00	Low
2/28/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$38.00	Low
2/5/2024	Needham & Company LLC	Lower Target	Buy ➝ Buy	$45.00 ➝ $38.00	Low
2/5/2024	HC Wainwright	Lower Target	Buy ➝ Buy	$52.00 ➝ $48.00	Low
12/8/2023	Wells Fargo & Company	Initiated Coverage	Overweight	$41.00	Low
11/10/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$54.00 ➝ $53.00	Low
10/16/2023	Leerink Partnrs	Reiterated Rating	Outperform		Low
10/4/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$45.00	Low
9/27/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$45.00	Low
9/27/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$50.00 ➝ $52.00	Low
9/15/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$45.00	Low
8/29/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$50.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$63.00	Low
8/10/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$51.00 ➝ $52.00	Low
8/10/2023	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$47.00 ➝ $48.00	Low
8/10/2023	Royal Bank of Canada	Lower Target		$57.00 ➝ $54.00	N/A
8/10/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$45.00	Low
8/10/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$50.00	N/A
8/8/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$57.00	Low
5/18/2023	Canaccord Genuity Group	Initiated Coverage	Buy	$48.00	Low
5/15/2023	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
5/10/2023	HC Wainwright	Lower Target		$55.00 ➝ $50.00	Low
5/10/2023	Oppenheimer	Boost Target		$44.00 ➝ $51.00	Low
5/1/2023	Cantor Fitzgerald	Boost Target		$52.00 ➝ $63.00	Low
5/1/2023	HC Wainwright	Boost Target		$54.00 ➝ $55.00	Low
4/20/2023	Needham & Company LLC	Reiterated Rating	Buy	$45.00	Low
4/12/2023	Robert W. Baird	Initiated Coverage	Outperform	$44.00	Low
3/28/2023	HC Wainwright	Reiterated Rating	Buy	$54.00	Low
3/20/2023	HC Wainwright	Boost Target		$53.00 ➝ $54.00	Low
3/13/2023	Citigroup	Lower Target	Buy	$55.00 ➝ $50.00	Low
3/10/2023	Needham & Company LLC	Reiterated Rating	Buy	$45.00	Low
3/10/2023	JPMorgan Chase & Co.	Lower Target	Overweight	$51.00 ➝ $47.00	Low
3/10/2023	Oppenheimer	Boost Target	Outperform	$43.00 ➝ $44.00	N/A
3/10/2023	Royal Bank of Canada	Lower Target	Outperform	$60.00 ➝ $58.00	Low
1/24/2023	SVB Leerink	Boost Target	Outperform	$33.00 ➝ $45.00	Low
1/24/2023	Citigroup	Boost Target	Buy	$36.00 ➝ $55.00	Low
1/23/2023	Needham & Company LLC	Boost Target	Buy	$40.00 ➝ $45.00	Low
1/23/2023	JPMorgan Chase & Co.	Boost Target		$42.00 ➝ $51.00	Low
1/23/2023	Cantor Fitzgerald	Boost Target	Overweight	$40.00 ➝ $52.00	Low
12/13/2022	Stifel Nicolaus	Initiated Coverage	Buy	$33.00	Low
12/7/2022	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$42.00	Low
11/9/2022	Royal Bank of Canada	Lower Target	Outperform	$52.00 ➝ $50.00	Low
9/1/2022	Citigroup	Initiated Coverage	Buy	$36.00	Low
8/9/2022	HC Wainwright	Boost Target	Buy	$45.00 ➝ $53.00	Low
7/20/2022	SVB Leerink	Initiated Coverage	Outperform	$33.00	Low
7/11/2022	Piper Sandler	Boost Target		$27.00 ➝ $40.00	N/A
7/11/2022	Cantor Fitzgerald	Boost Target		$28.00 ➝ $36.00	N/A
7/11/2022	Royal Bank of Canada	Boost Target		$35.00 ➝ $54.00	N/A
5/25/2022	Cantor Fitzgerald	Initiated Coverage	Overweight	$28.00	High
5/17/2022	Piper Sandler	Lower Target	Overweight	$63.00 ➝ $27.00	Medium
5/10/2022	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Medium
12/9/2021	Oppenheimer	Initiated Coverage	Outperform	$40.00	High
11/23/2021	Royal Bank of Canada	Initiated Coverage	Outperform	$38.00	High
11/3/2021	HC Wainwright	Initiated Coverage	Buy	$45.00	High
8/10/2021	Needham & Company LLC	Initiated Coverage	Buy	$40.00	Medium
4/22/2021	Piper Sandler	Boost Target	Overweight	$50.00 ➝ $63.00	High
4/20/2021	BTIG Research	Initiated Coverage	Buy	$51.00	Medium
4/5/2021	Citigroup	Initiated Coverage	Buy		Low
8/12/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
6/29/2020	Cowen	Initiated Coverage	Outperform		High
6/29/2020	Needham & Company LLC	Initiated Coverage	Buy	$40.00	High
6/29/2020	Citigroup	Initiated Coverage	Buy	$40.00	High
6/29/2020	Piper Sandler	Initiated Coverage	Overweight	$50.00	High

(Data available from 5/8/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

7 very positive mentions
9 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/11/2023

3 very positive mentions
1 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

11/10/2023

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/10/2023

1 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/9/2024

3 very positive mentions
5 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

2/8/2024

12 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/9/2024

2 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/8/2024

4 very positive mentions
9 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

5/8/2024

Current Sentiment

Recent Stories by Sentiment

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Today's Range

Now: $13.24

$13.21

$13.89

50 Day Range

MA: $14.32

$11.81

$17.21

52 Week Range

Now: $13.24

$11.21

$24.74

Volume

54,696 shs

Average Volume

380,455 shs

Market Capitalization

$798.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Pliant Therapeutics?: The following sell-side analysts have issued research reports on Pliant Therapeutics in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., HC Wainwright, JPMorgan Chase & Co., Leerink Partnrs, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, and Wells Fargo & Company.
View the latest analyst ratings for PLRX.
What is the current price target for Pliant Therapeutics?: 9 Wall Street analysts have set twelve-month price targets for Pliant Therapeutics in the last year. Their average twelve-month price target is $45.67, suggesting a possible upside of 244.9%. Cantor Fitzgerald has the highest price target set, predicting PLRX will reach $63.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $36.00 for Pliant Therapeutics in the next year.
View the latest price targets for PLRX.
What is the current consensus analyst rating for Pliant Therapeutics?: Pliant Therapeutics currently has 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLRX will outperform the market and that investors should add to their positions of Pliant Therapeutics.
View the latest ratings for PLRX.
What other companies compete with Pliant Therapeutics?: Other companies that are similar to Pliant Therapeutics include Tango Therapeutics, Evolus, Longboard Pharmaceuticals, Zentalis Pharmaceuticals and ALX Oncology. Learn More about companies similar to Pliant Therapeutics.
How do I contact Pliant Therapeutics' investor relations team?: Pliant Therapeutics' physical mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-481-6770 and its investor relations email address is [email protected]. The official website for Pliant Therapeutics is pliantrx.com. Learn More about contacing Pliant Therapeutics investor relations.

Pliant Therapeutics - PLRX Stock Price Target and Predictions

Analyst Price Target for PLRX

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.27 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Pliant Therapeutics?

What is the current price target for Pliant Therapeutics?

What is the current consensus analyst rating for Pliant Therapeutics?

What other companies compete with Pliant Therapeutics?

How do I contact Pliant Therapeutics' investor relations team?